This report studies the global Opioid Induced Constipation Drugs market, analyzes and researches the Opioid Induced Constipation Drugs development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
Ironwood Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Pfizer
Progenics Pharmaceuticals Inc
Shionogi & Co., Ltd
Allergan Plc
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma AG
Mundipharma International Limited
Ono Pharmaceutical Co., Ltd
Takeda Pharmaceutical Company Limited
Theravance Biopharma Inc
Valeant Pharmaceuticals International
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
Market segment by Regions/Countries, this report covers
United States
EU
Japan
China
India
Southeast Asia
Market segment by Type, Opioid Induced Constipation Drugs can be split into
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Other
Market segment by Application, Opioid Induced Constipation Drugs can be split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
Global Opioid Induced Constipation Drugs Market Size, Status and Forecast 2024
1 Industry Overview of Opioid Induced Constipation Drugs
1.1 Opioid Induced Constipation Drugs Market Overview
1.1.1 Opioid Induced Constipation Drugs Product Scope
1.1.2 Market Status and Outlook
1.2 Global Opioid Induced Constipation Drugs Market Size and Analysis by Regions
1.2.1 United States
1.2.2 EU
1.2.3 Japan
1.2.4 China
1.2.5 India
1.2.6 Southeast Asia
1.3 Opioid Induced Constipation Drugs Market by Type
1.3.1 Lubiprostone
1.3.2 Methyl Naltrexone Bromide
1.3.3 Naldemedine
1.3.4 Alvimopan
1.3.5 Other
1.4 Opioid Induced Constipation Drugs Market by End Users/Application
1.4.1 Hospital Pharmacies
1.4.2 Retail Pharmacies
1.4.3 Online Pharmacies
2 Global Opioid Induced Constipation Drugs Competition Analysis by Players
2.1 Opioid Induced Constipation Drugs Market Size (Value) by Players (2016 and 2019)
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future
3 Company (Top Players) Profiles
3.1 Ironwood Pharmaceuticals Inc
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Opioid Induced Constipation Drugs Revenue (Value) (2014-2019)
3.1.5 Recent Developments
3.2 Daiichi Sankyo Co Ltd
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Opioid Induced Constipation Drugs Revenue (Value) (2014-2019)
3.2.5 Recent Developments
3.3 Pfizer
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Opioid Induced Constipation Drugs Revenue (Value) (2014-2019)
3.3.5 Recent Developments
3.4 Progenics Pharmaceuticals Inc
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Opioid Induced Constipation Drugs Revenue (Value) (2014-2019)
3.4.5 Recent Developments
3.5 Shionogi & Co., Ltd
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Opioid Induced Constipation Drugs Revenue (Value) (2014-2019)
3.5.5 Recent Developments
3.6 Allergan Plc
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Opioid Induced Constipation Drugs Revenue (Value) (2014-2019)
3.6.5 Recent Developments
3.7 Nektar Therapeutics
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 Opioid Induced Constipation Drugs Revenue (Value) (2014-2019)
3.7.5 Recent Developments
3.8 Purdue Pharma
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 Opioid Induced Constipation Drugs Revenue (Value) (2014-2019)
3.8.5 Recent Developments
3.9 S.L.A. Pharma AG
3.9.1 Company Profile
3.9.2 Main Business/Business Overview
3.9.3 Products, Services and Solutions
3.9.4 Opioid Induced Constipation Drugs Revenue (Value) (2014-2019)
3.9.5 Recent Developments
3.10 Mundipharma International Limited
3.10.1 Company Profile
3.10.2 Main Business/Business Overview
3.10.3 Products, Services and Solutions
3.10.4 Opioid Induced Constipation Drugs Revenue (Value) (2014-2019)
3.10.5 Recent Developments
3.11 Ono Pharmaceutical Co., Ltd
3.12 Takeda Pharmaceutical Company Limited
3.13 Theravance Biopharma Inc
3.14 Valeant Pharmaceuticals International
3.15 Cosmo Pharmaceuticals SA
3.16 Daewoong Pharmaceutical
3.17 C.B. Fleet Company
3.18 Sucampo Pharmaceuticals
4 Global Opioid Induced Constipation Drugs Market Size by Type and Application (2014-2019)
4.1 Global Opioid Induced Constipation Drugs Market Size by Type (2014-2019)
4.2 Global Opioid Induced Constipation Drugs Market Size by Application (2014-2019)
4.3 Potential Application of Opioid Induced Constipation Drugs in Future
4.4 Top Consumer/End Users of Opioid Induced Constipation Drugs
5 United States Opioid Induced Constipation Drugs Development Status and Outlook
5.1 United States Opioid Induced Constipation Drugs Market Size (2014-2019)
5.2 United States Opioid Induced Constipation Drugs Market Size and Market Share by Players (2016 and 2019)
6 EU Opioid Induced Constipation Drugs Development Status and Outlook
6.1 EU Opioid Induced Constipation Drugs Market Size (2014-2019)
6.2 EU Opioid Induced Constipation Drugs Market Size and Market Share by Players (2016 and 2019)
7 Japan Opioid Induced Constipation Drugs Development Status and Outlook
7.1 Japan Opioid Induced Constipation Drugs Market Size (2014-2019)
7.2 Japan Opioid Induced Constipation Drugs Market Size and Market Share by Players (2016 and 2019)
8 China Opioid Induced Constipation Drugs Development Status and Outlook
8.1 China Opioid Induced Constipation Drugs Market Size (2014-2019)
8.2 China Opioid Induced Constipation Drugs Market Size and Market Share by Players (2016 and 2019)
9 India Opioid Induced Constipation Drugs Development Status and Outlook
9.1 India Opioid Induced Constipation Drugs Market Size (2014-2019)
9.2 India Opioid Induced Constipation Drugs Market Size and Market Share by Players (2016 and 2019)
10 Southeast Asia Opioid Induced Constipation Drugs Development Status and Outlook
10.1 Southeast Asia Opioid Induced Constipation Drugs Market Size (2014-2019)
10.2 Southeast Asia Opioid Induced Constipation Drugs Market Size and Market Share by Players (2016 and 2019)
11 Market Forecast by Regions, Type and Application (2019-2024)
11.1 Global Opioid Induced Constipation Drugs Market Size (Value) by Regions (2019-2024)
11.1.1 United States Opioid Induced Constipation Drugs Revenue and Growth Rate (2019-2024)
11.1.2 EU Opioid Induced Constipation Drugs Revenue and Growth Rate (2019-2024)
11.1.3 Japan Opioid Induced Constipation Drugs Revenue and Growth Rate (2019-2024)
11.1.4 China Opioid Induced Constipation Drugs Revenue and Growth Rate (2019-2024)
11.1.5 India Opioid Induced Constipation Drugs Revenue and Growth Rate (2019-2024)
11.1.6 Southeast Asia Opioid Induced Constipation Drugs Revenue and Growth Rate (2019-2024)
11.2 Global Opioid Induced Constipation Drugs Market Size (Value) by Type (2019-2024)
11.3 Global Opioid Induced Constipation Drugs Market Size by Application (2019-2024)
12 Opioid Induced Constipation Drugs Market Dynamics
12.1 Opioid Induced Constipation Drugs Market Opportunities
12.2 Opioid Induced Constipation Drugs Challenge and Risk
12.2.1 Competition from Opponents
12.2.2 Downside Risks of Economy
12.3 Opioid Induced Constipation Drugs Market Constraints and Threat
12.3.1 Threat from Substitute
12.3.2 Government Policy
12.3.3 Technology Risks
12.4 Opioid Induced Constipation Drugs Market Driving Force
12.4.1 Growing Demand from Emerging Markets
12.4.2 Potential Application
13 Market Effect Factors Analysis
13.1 Technology Progress/Risk
13.1.1 Substitutes
13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs Trend/Customer Preference
13.3 External Environmental Change
13.3.1 Economic Fluctuations
13.3.2 Other Risk Factors
14 Research Finding/Conclusion
15 Appendix
Methodology
Analyst Introduction
Data Source